AI 聊天
Loading data for DRTSW — first visit, this takes a few seconds.

Alpha Tau Medical Ltd.

DRTSW · NasdaqCM · USD

3.79 -0.21 (-5.25%)

收盤價: Sep 11, 2026, 6:00 PM

市值
成交量
77.2K

Alpha Tau Medical Ltd.(DRTSW)股價、分析與資料

內在價值

正在載入內在價值…

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →

正在載入...

最新財報

已通報較預期YoY 變更
營收n/an/a
EPSn/an/a

下次財報

查看財報詳情 →

指標

買價
0
市值
n/a
淨利(ttm)
-92.6M
1.21
n/a
n/a
n/a
P/B (ttm)
8.05
P/S (ttm)
n/a
財報日期
n/a
賣價
0
成交量
77,197
20 日平均成交量
n/a
開盤價
0.33
前收盤價
4.00
當日區間
3.72 - 4.03
52 週範圍
3.72 - 4.03
股利
n/a
除息日
n/a

關於 Alpha Tau Medical Ltd.

查看公司資料 →
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel. ·

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

產業
類股
IPO 日期 Jul 17, 2026
員工 121
證券交易所 NasdaqCM
股票代號 DRTSW